Glucagon Breaks Down Glucose: Technical Pros and Cons
Abstract: Glucagon, a 29-amino-acid peptide hormone, triggers hepatic glycogenolysis, breaking down glucose before cellular uptake—a key distinction from insulin. This mechanism offers therapeutic advantages in severe hypoglycemia management and metabolic research. However, technical drawbacks include short half-life ( 6 min), instability in aqueous solutions, and high manufacturing costs. Market trends show rising demand for stable glucagon analogs (e.g., dasiglucagon) and dual-agonist peptides (GLP-1/glucagon). Leading brands (Novo Nordisk, Xeris) differ in formulation stability and delivery devices. Regulatory compliance (FDA, EMA) and cold-chain logistics (2–8°C) are critical for product integrity. Understanding these pros and cons guides peptide selection for clinical and research applications.